
Denosumab-adet now covers all 3 Xgeva indications, widening lower-cost treatment access for cancer patients with bone complications.
by Gail Sofer, BioReliance Plasma products have been associated with high levels of risk from viral contamination; therefore, most viral inactivation methods described in the literature during the past ten years have addressed plasma and plasma products. Plasma is the largest group to cover, and Part 3 takes two articles in our series to describe the many methods published. This article covers heat and solvent/detergent inactivation treatments for plasma.
about 24 years ago
Reexamining the Set It and Forget It Approachabout 24 years ago
Security in the Corporate Homelandabout 24 years ago
Integrating New Technology into Blood Plasma Fractionationabout 24 years ago
Attack Mounts on Pharmaceutical Pricesabout 24 years ago
If a Tree Fell in the Forest





